BioSyent (RX) Stock Overview
Acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Rewards
Risk Analysis
RX passed our risk checks.
RX Community Fair Values
Create NarrativeSee what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.
BioSyent Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$14.55 |
| 52 Week High | CA$15.80 |
| 52 Week Low | CA$10.65 |
| Beta | 0.64 |
| 1 Month Change | -2.22% |
| 3 Month Change | -2.55% |
| 1 Year Change | 35.10% |
| 3 Year Change | 89.45% |
| 5 Year Change | 94.00% |
| Change since IPO | 1,193.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| RX | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -0.6% | -4.0% | 0.6% |
| 1Y | 35.1% | 53.0% | 34.2% |
Return vs Industry: RX underperformed the Canadian Pharmaceuticals industry which returned 53% over the past year.
Return vs Market: RX matched the Canadian Market which returned 34.2% over the past year.
Price Volatility
| RX volatility | |
|---|---|
| RX Average Weekly Movement | 4.2% |
| Pharmaceuticals Industry Average Movement | 11.0% |
| Market Average Movement | 10.3% |
| 10% most volatile stocks in CA Market | 18.1% |
| 10% least volatile stocks in CA Market | 3.9% |
Stable Share Price: RX has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: RX's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | René Goehrum | www.biosyent.com |
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.
BioSyent Inc. Fundamentals Summary
| RX fundamental statistics | |
|---|---|
| Market cap | CA$166.43m |
| Earnings (TTM) | CA$9.01m |
| Revenue (TTM) | CA$43.05m |
Is RX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RX income statement (TTM) | |
|---|---|
| Revenue | CA$43.05m |
| Cost of Revenue | CA$10.09m |
| Gross Profit | CA$32.96m |
| Other Expenses | CA$23.95m |
| Earnings | CA$9.01m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
May 14, 2026
| Earnings per share (EPS) | 0.79 |
| Gross Margin | 76.57% |
| Net Profit Margin | 20.93% |
| Debt/Equity Ratio | 0% |
How did RX perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/14 20:43 |
| End of Day Share Price | 2026/05/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
BioSyent Inc. is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tania Armstrong-Whitworth | ATB Cormark Historical (Cormark Securities) |
| David Martin | Bloom Burton & Co. |
| Scott Curtis | Cantor Fitzgerald Canada Corporation |